Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

Journal of Immunotherapy

Volumn 37, Issue 2, 2014, Pages 84-92

  Wada, Hisashi ^a   Isobe, Midori ^c   Kakimi, Kazuhiro ^g   Mizote, Yu ^c   Eikawa, Shingo ^c   Sato, Eiichi ^h   Takigawa, Nagio ^e   Kiura, Katsuyuki ^e   Tsuji, Kazuhide ^f   Iwatsuki, Keiji ^f   Yamasaki, Makoto ^a   Miyata, Hiroshi ^a   Matsushita, Hirokazu ^g   Udono, Heiichiro ^e   Seto, Yasuyuki ^g   Yamada, Kazuhiro ⁱ   Nishikawa, Hiroyoshi ^b   Pan, Linda ^j   Venhaus, Ralph ^j   Oka, Mikio ^c   Doki, Yuichiro ^a   Nakayama, Eiichi ^d   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ CANCER INSTITUTE HOSPITAL   (Japan)

^j LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

more..

Author keywords

CT antigen; NY ESO 1; overlapping peptide vaccine; TLR

Indexed keywords

AGED; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; EPITOPES, T-LYMPHOCYTE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, HUMORAL; LYMPHOCYTE ACTIVATION; MALE; MANNITOL; MEMBRANE PROTEINS; MIDDLE AGED; OLEIC ACIDS; PEPTIDE FRAGMENTS; PICIBANIL; TREATMENT OUTCOME; VACCINATION; VACCINES, SUBUNIT;

EID: 84894484360     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000017     Document Type: Article

References (32)

1. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94: 1914-1918.
2. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
3. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-335.
4. Quakkelaar ED, Melief CJ. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol. 2012;114:77-106.
5. Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011;69:296-303.
6. Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011;23:286-292.
7. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res. 2011;17:5725-5735.
8. Trumpfheller C, Longhi MP, Caskey M, et al. Dendritic celltargeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med. 2012;271:183-192.
9. Kakimi K, Isobe M, Uenaka A, et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011;129: 2836-2846.
10. Melief CJ. Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. J Immunother. 2012;35:215-216.
11. Zeestraten EC, Speetjens FM, Welters MJ, et al. Addition of interferon-a to the p53-SLPs vaccine results in increased production of interferon-g in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer. 2013;132: 1581-1591.
12. Bijker MS, van den Eeden SJ, Franken KL, et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol. 2007; 179:5033-5040.
13. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351-360.
14. Dunne A, Marshall NA, Mills KH. TLR based therapeutics. Curr Opin Pharmacol. 2011;11:404-411.
15. Flynn BJ, Kastenmu ller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A. 2011;108:7131-7136.
16. Morse MA, Chapman R, Powderly J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res. 2011;17: 4844-4853.
17. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-650.
18. Aoki M, Ueda S, Nishikawa H, et al. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NYESO- 1 and CHP-HER2 with OK-432. Vaccine. 2009;27: 6854-6861.
19. Okamoto M, Oshikawa T, Tano T, et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and toll-like receptor 4 signaling. J Immunother. 2006;29:78-86.
20. Hironaka K, Yamaguchi Y, Okita R, et al. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res. 2006;26: 3701-3707.
21. Hirayama M, Nishikawa H, Nagata Y, et al. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol. 2013;43:989-1000.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
23. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res. 2009;15:7412-7420.
24. Kawabata R, Wada H, Isobe M, et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer. 2007;120:2178-2184.
25. Uenaka A, Wada H, Isobe M, et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NYESO- 1 protein. Cancer Immun. 2007;7:9.
26. Kawada J, Wada H, Isobe M, et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2012;130: 584-592.
27. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108:1119-1125.
28. Tsuji K, Hamada T, Uenaka A, et al. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother. 2008;57:1429-1437.
29. Wada H, Sato E, Uenaka A, et al. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2008;123:2362-2369.
30. Gay NJ, Gangloff M. Structure of toll-like receptors. Handb Exp Pharmacol. 2008;181-200.
31. Eikawa S, Kakimi K, Isobe M, et al. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NYESO- 1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013;132: 345-354.
32. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497-6508.